miR ‐3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi‐targets
Journal of Cellular and Molecular Medicine · 2023
DOI: 10.1111/jcmm.17880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von Ling Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: MicroRNAs, Tumor Suppressor Protein p53, Signal Transduction, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangxi Key Laboratory for Individualized Cancer Therapy, Jiangxi Provincial Outstanding Young Talents projects, Jiangxi Provincial Young Talents projects.
Abstract (Originalsprache)
Background
Malignant cell growth and chemoresistance, the main obstacles in treating gastrointestinal cancer (GIC), rely on the Hippo and p53 signalling pathways. However, the upstream regulatory mechanisms of these pathways remain complex and poorly understood.
Methods
Immunohistochemistry (IHC), western blot and RT‐qPCR were used to analyse the expression of RNF146, miR‐3133 and key components of Hippo and p53 pathway. CCK‐8, colony formation, drug sensitivity assays and murine xenograft models were used to investigate the effect of RNF146 and miR‐3133 in GIC. Further exploration of the upstream regulatory mechanism was performed using bioinformatics analysis, dual‐luciferase reporter gene, immunoprecipitation assays and bisulfite sequencing PCR (BSP).
Results
Clinical samples, in vitro and in vivo experiments demonstrated that RNF146 exerts oncogenic effects in GIC by regulating the Hippo pathway. Bioinformatics analysis identified a novel miRNA, miR‐3133, as an upstream regulatory factor of RNF146. fluorescence in situ hybridization and RT‐qPCR assays revealed that miR‐3133 was less expressed in gastrointestinal tumour tissues and was associated with adverse pathological features. Functional assays and animal models showed that miR‐3133 promoted the proliferation and chemotherapy sensitivity of GIC cells. miR‐3133 affected YAP1 protein expression by targeting RNF146, AGK and CUL4A, thus activating the Hippo pathway. miR‐3133 inhibited p53 protein degradation and extended p53's half‐life by targeting USP15, SPIN1. BSP experiments confirmed that miR‐3133 promoter methylation is an important reason for its low expression. Conclusion miR‐3133 inhibits GIC progression by activating the Hippo and p53 signalling pathways via multi‐targets, including RNF146, thereby providing prognostic factors and valuable potential therapeutic targets for GIC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- Jiangxi Key Laboratory for Individualized Cancer Therapy, Nanchang, China.
ORCID-Profile: Jianping Xiong, Xiaojun Xiang
Förderung
- Jiangxi Key Laboratory for Individualized Cancer Therapy
- Jiangxi Provincial Outstanding Young Talents projects
- Jiangxi Provincial Young Talents projects
- Key Research and Development Programs of Jiangxi Province
- Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- Special fund for innovation of Postgraduates in Jiangxi Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, L., Guo, H., Liao, Q., Zou, J., Le, Y., Fang, Z., Xiong, J., Huang, S., Deng, J., & Xiang, X. (2023). miR ‐3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi‐targets. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17880
Vancouver
Zhou L, Guo H, Liao Q, Zou J, Le Y, Fang Z, et al. miR ‐3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi‐targets. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17880
BibTeX
@article{Zhou2023,
author = {Zhou, Ling and Guo, Hui and Liao, Quan and Zou, Jianping and Le, Yi and Fang, Ziling and Xiong, Jianping and Huang, Shanshan and Deng, Jun and Xiang, Xiaojun},
title = {miR ‐3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi‐targets},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
doi = {10.1111/jcmm.17880}
}
EUVIMED